ArticleAmerican journal of translational research2019
MicroRNA-765 alleviates the malignant progression of breast cancer via interacting with EZH1.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Decoding the Epigenome of Breast Cancer.International journal of molecular sciences · 2025Review
- MicroRNA-Mediated Regulation of Histone-Modifying Enzymes in Cancer: Mechanisms and Therapeutic Implications.Biomolecules · 2023Review
- The Role of Histone Modification in DNA Replication-Coupled Nucleosome Assembly and Cancer.International journal of molecular sciences · 2023Review
- Article
- Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer.Journal of oncology · 2022Review
- MicroRNA-20a Suppresses Tumor Proliferation and Metastasis in Hepatocellular Carcinoma by Directly Targeting EZH1.Frontiers in oncology · 2021Article
- miRNA Expression Profiles in Luminal A Breast Cancer-Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment.International journal of molecular sciences · 2020Review
- EZH2 inhibition: a promising strategy to prevent cancer immune editing.Epigenomics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To detect the expression pattern of microRNA-765 in breast cancer (BCa) and its regulatory effect on the disease progression. Expression level of microRNA-765 in 66 paired BCa tissues and matched normal tissues was detected by qRT-PCR. The relationship between microRNA-765 level and clinical data of BCa patients was analyzed. Subsequently, microRNA-765 level in BCa cell lines was examined as well. Changes in proliferative, migratory and invasive abilities in MCF-7 and SKBR3 cells either overexpressing microRNA-765 or not were evaluated. Furthermore, expression level of EZH1 in BCa tissues and cell lines was determined. The regulatory interaction between microRNA-765 and EZH1 was identified. Finally, the role of microRNA-765/EZH1 axis in the progression of BCa was assessed. MicroRNA-765 was downregulated in BCa tissues relative to matched normal ones. BCa patients expressing low expression of microRNA-765 presented higher tumor stage, higher metastatic rate and worse overall survival. Overexpression of microRNA-765 attenuated proliferative, migratory and invasive abilities in MCF-7 and SKBR3 cells. In addition, EZH1 was upregulated in BCa tissues and cell lines. EZH1 level was negatively regulated by microRNA-765 in BCa. Overexpression of EZH1 reversed the inhibitory effects of microRNA-765 on malignant progression of BCa. MicroRNA-765 is downregulated in BCa and closely correlated to tumor stage, lymphatic metastasis, distant metastasis and poor prognosis of BCa patients. Overexpression of microRNA-765 attenuates the malignant progression of BCa through negatively regulating EZH1.
Indexed as
Identifiers
31396353PMC6684906W3020868400What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.